Dialysis-Associated Hypertension Treated with Telmisartan – DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized Trial

Treatment of hypertension in hemodialysis (HD) patients is characterised by lack of evidence for both the blood pressure (BP) target goal and the recommended drug class to use. Telmisartan, an Angiotensin receptor blocker (ARB) that is metabolised in the liver and not excreted via HD extracorporeal...

Descripción completa

Detalles Bibliográficos
Autores principales: Huber, Matthias, Treutler, Till, Martus, Peter, Kurzidim, Antje, Kreutz, Reinhold, Beige, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832496/
https://www.ncbi.nlm.nih.gov/pubmed/24260194
http://dx.doi.org/10.1371/journal.pone.0079322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3832496/
https://www.ncbi.nlm.nih.gov/pubmed/24260194
http://dx.doi.org/10.1371/journal.pone.0079322

Ejemplares similares